Compare DECK & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DECK | CYTK |
|---|---|---|
| Founded | 1973 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 10.7B |
| IPO Year | 1996 | 2004 |
| Metric | DECK | CYTK |
|---|---|---|
| Price | $78.00 | $65.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 19 |
| Target Price | ★ $122.45 | $89.26 |
| AVG Volume (30 Days) | ★ 2.8M | 1.6M |
| Earning Date | 05-21-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.90 | N/A |
| EPS | ★ 0.94 | N/A |
| Revenue | ★ $5,472,296,000.00 | $13,368,000.00 |
| Revenue This Year | $11.16 | $7.37 |
| Revenue Next Year | $6.96 | $310.19 |
| P/E Ratio | $83.04 | ★ N/A |
| Revenue Growth | ★ 9.76 | N/A |
| 52 Week Low | $77.37 | $54.30 |
| 52 Week High | $122.29 | $88.31 |
| Indicator | DECK | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 34.39 | 30.62 |
| Support Level | $77.37 | $63.96 |
| Resistance Level | $83.00 | $67.04 |
| Average True Range (ATR) | 2.05 | 2.20 |
| MACD | 0.40 | -0.40 |
| Stochastic Oscillator | 12.24 | 3.37 |
Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2026, Ugg and Hoka accounted for 50% and 47% of total sales, respectively. The firm also markets a niche sandal brand Teva. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and has more than 200 company-operated stores, about half of which are outlets. The firm generated 58% of its fiscal 2026 sales in the United States.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.